SCHEMBL3970355

SCHEMBL3970355

N#Cc1ccc2cc(-c3nc(Cl)ncc3Cl)sc2c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.33
LRRK2 Q5S007 1/20 0.32
DYRK1A Q13627 1/20 0.32
CSNK1A1 P48729 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32
ACLY P53396 1/20 0.32
KDM1A O60341 1/20 0.31
ADORA2A P29274 1/20 0.31
CCNT1 O60563 1/20 0.31
CCNK O75909 1/20 0.31
CCNE1 P24864 1/20 0.31
CDK2 P24941 1/20 0.31
CDK9 P50750 1/20 0.31
CDK12 Q9NYV4 1/20 0.31
PLAU P00749 1/20 0.30
GRM5 P41594 1/20 0.30
RPS6KA5 O75582 1/20 0.30
DHPS P49366 1/20 0.30
CYP17A1 P05093 1/20 0.30
CYP11B1 P15538 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3963487 0.80 RPS6KA5 (0.32) RPS6KA5
SCHEMBL3965523 0.77 APP (0.41) APPKDM1AADORA2APLAURPS6KA5
SCHEMBL3966612 0.76 ESR1 (0.31) RPS6KA5
SCHEMBL3962095 0.72 FGFR1 (0.44)
SCHEMBL16797309 0.72 KDM1A (0.49) CSNK1A1CLK4KDM1APLAUGRM5
SCHEMBL3964580 0.72 HDAC6 (0.44) DYRK1APLAU
SCHEMBL3965404 0.72 HDAC1 (0.49) CYP11B1CYP11B2
SCHEMBL3361910 0.71 CYP11B2 (0.42) RPS6KA5CYP11B1CYP11B2
SCHEMBL3965558 0.67 PKM (0.49) LRRK2
SCHEMBL12831125 0.67 DYRK1A (0.41) APPDYRK1ADHPSCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG APP 645/4885LRRK2 868/4885DYRK1A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.